Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1994 Jul-Aug;18(4):594-8; discussion 599.
doi: 10.1007/BF00353773.

Clinical course of metastatic parathyroid cancer

Affiliations

Clinical course of metastatic parathyroid cancer

K Sandelin et al. World J Surg. 1994 Jul-Aug.

Abstract

In a retrospective study the clinical course of 40 patients with symptomatic persistent or recurrent parathyroid cancer was analyzed in order to assess the value of aggressive surgical intervention. Recurrence was diagnosed after a median period of 33 months (1-228 months). Twenty-two patients had locoregional disease, whereas 14 patients had both local and distant spread. The remaining four patients had distant spread. Patients with just locoregional disease were subject to one to nine reoperative procedures. The median survival time from the last operation was 39 months (1-204 months). Eight patients then had no evidence of disease, three were hypercalcemic and 9 of 11 had died of parathyroid cancer. Distant spread was demonstrated in 17 of 40 patients. Pulmonary metastases predominated (14 of 17). Surgical excision was performed in 9 of 14 cases. Of these nine, two patients had a subsequent disease-free interval of 36+ and 72+ months, respectively. One patient was reported hypercalcemic after 84 months, whereas five patients died of cancer between 4 and 60 months after their last surgical exploration. One patient was lost to follow-up. In all, 21 patients (53%) died of parathyroid cancer. Conspicuous nuclear atypia and frequent mitoses predominated. Image cytometric DNA analysis showed high rates for all three groups (median p90 = 80%, range 21-98%).

PubMed Disclaimer

References

    1. World J Surg. 1992 Jul-Aug;16(4):724-31 - PubMed
    1. Lancet. 1989 Nov 18;2(8673):1180-2 - PubMed
    1. Cancer. 1990 Oct 1;66(7):1555-62 - PubMed
    1. J Clin Endocrinol Metab. 1988 Oct;67(4):779-84 - PubMed
    1. Surgery. 1991 Dec;110(6):978-86; discussion 986-8 - PubMed

Publication types